Neogen Corporation (NEOG) Stock

Understand Neogen Corporation: how it makes money

Neogen sells rapid diagnostic test kits that detect pathogens, allergens, and chemical residues in food, feed, and animal products, earning revenue through recurring consumable purchases from labs and processors. The Food Safety line drives roughly 80% of sales, and about three-quarters of customers buy across multiple categories, creating a cross-sell pull-through model.

Recurring test-kit consumption (75% of customers buy multiple categories) produces predictable pull-through revenue, but the 47% gross margin leaves minimal room to absorb R&D step-ups or price concessions without pushing operating results deeper into negative territory.

Business quality (Weak): Weak. Negative operating margin and a 4% top-line decline undercut the structural merits of the recurring-consumable model and 75% multi-category penetration.

Bull case

• Margin Tailwind From PETRIFILM: The PETRIFILM transition could deliver 200-300 basis points of gross-margin expansion, giving the 47% gross margin meaningful headroom even before volume growth re-accelerates.
• Food Safety Categories Accelerating: Key Food Safety categories posted 9%-10% growth in the quarter, suggesting the 80%-of-revenue core business is re-accelerating after the prior year's softness.
• Debt Paydown From Genomics: Genomics proceeds are earmarked for debt reduction and business investment, which should lower the financial drag on the already negative 2% operating margin.

Bear case

• Low Single-Digit Growth Path: FY27 guidance reflects only approximately 3% core growth, keeping headline revenue expansion anemic even in a base-case scenario.
• R&D Cost Spike Ahead: R&D spending will rise 50% before new innovations meaningfully contribute to revenue, pressuring the already negative 2% operating margin in the near term.
• Customer Inflation Squeeze: Food producers continue facing inflationary cost pressures linked to the Iran War, which could suppress discretionary testing spend and compound the 4% YoY revenue decline.

Neogen Corporation earnings call transcripts

• NEOG Q4 FY26 earnings call transcript (reported 2026-07-30) · analysis
• NEOG Q2 FY26 earnings call transcript (reported 2026-01-08) · analysis

All NEOG earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Myriad Genetics, Inc. (MYGN)
• QuidelOrtho Corporation (QDEL)
• Caris Life Sciences, Inc. (CAI)
• Lumexa Imaging Holdings, Inc. Common Stock (LMRI)
• Guardant Health, Inc. (GH)
• Sotera Health Company (SHC)
• Veracyte, Inc. (VCYT)
• CareDx, Inc (CDNA)